- Home
- NTRA vs PHM Comparison
NTRA vs PHM Comparison
Compare NTRA & PHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- PHM
- Stock Information
- Founded
- NTRA 2003
- PHM 1950
- Country
- NTRA United States
- PHM United States
- Employees
- NTRA N/A
- PHM N/A
- Industry
- NTRA Medical Specialities
- PHM Homebuilding
- Sector
- NTRA Health Care
- PHM Consumer Discretionary
- Exchange
- NTRA Nasdaq
- PHM Nasdaq
- Market Cap
- NTRA 27.0B
- PHM 23.0B
- IPO Year
- NTRA 2015
- PHM N/A
- Fundamental
- Price
- NTRA $205.15
- PHM $118.67
- Analyst Decision
- NTRA Strong Buy
- PHM Buy
- Analyst Count
- NTRA 16
- PHM 13
- Target Price
- NTRA $220.38
- PHM $134.31
- AVG Volume (30 Days)
- NTRA 1.4M
- PHM 2.2M
- Earning Date
- NTRA 11-06-2025
- PHM 10-21-2025
- Dividend Yield
- NTRA N/A
- PHM 0.74%
- EPS Growth
- NTRA N/A
- PHM N/A
- EPS
- NTRA N/A
- PHM 13.01
- Revenue
- NTRA $2,116,676,000.00
- PHM $17,622,999,000.00
- Revenue This Year
- NTRA $25.70
- PHM N/A
- Revenue Next Year
- NTRA $15.42
- PHM N/A
- P/E Ratio
- NTRA N/A
- PHM $9.10
- Revenue Growth
- NTRA 38.17
- PHM 1.76
- 52 Week Low
- NTRA $125.38
- PHM $88.07
- 52 Week High
- NTRA $212.21
- PHM $142.11
- Technical
- Relative Strength Index (RSI)
- NTRA 65.15
- PHM 39.59
- Support Level
- NTRA $182.20
- PHM $117.74
- Resistance Level
- NTRA $212.21
- PHM $122.72
- Average True Range (ATR)
- NTRA 8.09
- PHM 2.92
- MACD
- NTRA 0.00
- PHM 0.26
- Stochastic Oscillator
- NTRA 75.84
- PHM 44.46
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.